| Study . | Risk factors (%) . | Medication history (%) . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Hypertension . | Hypercholesterolaemia . | Diabetes Mellitus . | Tobacco use . | Aspirin . | Beta-blockers . | ACE/angiotensin receptor blockers* . | Statins . | Loop diuretic . | |
| Weinsaft 201611 | 43.8 | 49.8 | 23.4 | N/R | 99.0 | 95.5 | 58.7 | 97.0 | 6.0 |
| Weinsaft 20093 | 66.9 | 88.4 | 33.1 | 33.1 | 85.1 | 77.7 | 66.9 | 79.3 | 16.5 |
| Kim 201724 | 47.3 | 45.9 | 24.3 | 27.0 | 97.3 | 98.6 | 73.0 | 94.6 | N/R |
| Weinsaft 201118 | 61.3 | 38.7 | 35.4 | 23.9 | 57.6 | 51.4 | 45.7 | N/R | 31.3 |
| Delewi 201219 | 27.8 | 19.6 | 6.2 | 46.9 | 96.4 | N/R | N/R | N/R | N/R |
| Garg 201220 | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R |
| Meurin 201521 | 33.0 | 8.0 | 20.0 | 43.0 | 100.0 | 100.0 | 99.0 | 99.0 | N/R |
| Sürder 201522 | 41.8 | 41.2 | 10.7 | 58.2 | 97.3 | 91.1 | 85.7 | 99.1 | 33.9 |
| Chaosuwannakit 202123 | N/R | N/R | N/R | N/R | 76.2 | N/R | N/R | N/R | N/R |
| Phan 201925 | 47.1 | 45.7 | 19.5 | 57.6 | N/R | 94.3 | 82.9 | 97.6 | 7.1 |
| Kim 201426 | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R |
| Study . | Risk factors (%) . | Medication history (%) . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Hypertension . | Hypercholesterolaemia . | Diabetes Mellitus . | Tobacco use . | Aspirin . | Beta-blockers . | ACE/angiotensin receptor blockers* . | Statins . | Loop diuretic . | |
| Weinsaft 201611 | 43.8 | 49.8 | 23.4 | N/R | 99.0 | 95.5 | 58.7 | 97.0 | 6.0 |
| Weinsaft 20093 | 66.9 | 88.4 | 33.1 | 33.1 | 85.1 | 77.7 | 66.9 | 79.3 | 16.5 |
| Kim 201724 | 47.3 | 45.9 | 24.3 | 27.0 | 97.3 | 98.6 | 73.0 | 94.6 | N/R |
| Weinsaft 201118 | 61.3 | 38.7 | 35.4 | 23.9 | 57.6 | 51.4 | 45.7 | N/R | 31.3 |
| Delewi 201219 | 27.8 | 19.6 | 6.2 | 46.9 | 96.4 | N/R | N/R | N/R | N/R |
| Garg 201220 | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R |
| Meurin 201521 | 33.0 | 8.0 | 20.0 | 43.0 | 100.0 | 100.0 | 99.0 | 99.0 | N/R |
| Sürder 201522 | 41.8 | 41.2 | 10.7 | 58.2 | 97.3 | 91.1 | 85.7 | 99.1 | 33.9 |
| Chaosuwannakit 202123 | N/R | N/R | N/R | N/R | 76.2 | N/R | N/R | N/R | N/R |
| Phan 201925 | 47.1 | 45.7 | 19.5 | 57.6 | N/R | 94.3 | 82.9 | 97.6 | 7.1 |
| Kim 201426 | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R |
N/R = data not reported in primary paper.
| Study . | Risk factors (%) . | Medication history (%) . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Hypertension . | Hypercholesterolaemia . | Diabetes Mellitus . | Tobacco use . | Aspirin . | Beta-blockers . | ACE/angiotensin receptor blockers* . | Statins . | Loop diuretic . | |
| Weinsaft 201611 | 43.8 | 49.8 | 23.4 | N/R | 99.0 | 95.5 | 58.7 | 97.0 | 6.0 |
| Weinsaft 20093 | 66.9 | 88.4 | 33.1 | 33.1 | 85.1 | 77.7 | 66.9 | 79.3 | 16.5 |
| Kim 201724 | 47.3 | 45.9 | 24.3 | 27.0 | 97.3 | 98.6 | 73.0 | 94.6 | N/R |
| Weinsaft 201118 | 61.3 | 38.7 | 35.4 | 23.9 | 57.6 | 51.4 | 45.7 | N/R | 31.3 |
| Delewi 201219 | 27.8 | 19.6 | 6.2 | 46.9 | 96.4 | N/R | N/R | N/R | N/R |
| Garg 201220 | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R |
| Meurin 201521 | 33.0 | 8.0 | 20.0 | 43.0 | 100.0 | 100.0 | 99.0 | 99.0 | N/R |
| Sürder 201522 | 41.8 | 41.2 | 10.7 | 58.2 | 97.3 | 91.1 | 85.7 | 99.1 | 33.9 |
| Chaosuwannakit 202123 | N/R | N/R | N/R | N/R | 76.2 | N/R | N/R | N/R | N/R |
| Phan 201925 | 47.1 | 45.7 | 19.5 | 57.6 | N/R | 94.3 | 82.9 | 97.6 | 7.1 |
| Kim 201426 | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R |
| Study . | Risk factors (%) . | Medication history (%) . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Hypertension . | Hypercholesterolaemia . | Diabetes Mellitus . | Tobacco use . | Aspirin . | Beta-blockers . | ACE/angiotensin receptor blockers* . | Statins . | Loop diuretic . | |
| Weinsaft 201611 | 43.8 | 49.8 | 23.4 | N/R | 99.0 | 95.5 | 58.7 | 97.0 | 6.0 |
| Weinsaft 20093 | 66.9 | 88.4 | 33.1 | 33.1 | 85.1 | 77.7 | 66.9 | 79.3 | 16.5 |
| Kim 201724 | 47.3 | 45.9 | 24.3 | 27.0 | 97.3 | 98.6 | 73.0 | 94.6 | N/R |
| Weinsaft 201118 | 61.3 | 38.7 | 35.4 | 23.9 | 57.6 | 51.4 | 45.7 | N/R | 31.3 |
| Delewi 201219 | 27.8 | 19.6 | 6.2 | 46.9 | 96.4 | N/R | N/R | N/R | N/R |
| Garg 201220 | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R |
| Meurin 201521 | 33.0 | 8.0 | 20.0 | 43.0 | 100.0 | 100.0 | 99.0 | 99.0 | N/R |
| Sürder 201522 | 41.8 | 41.2 | 10.7 | 58.2 | 97.3 | 91.1 | 85.7 | 99.1 | 33.9 |
| Chaosuwannakit 202123 | N/R | N/R | N/R | N/R | 76.2 | N/R | N/R | N/R | N/R |
| Phan 201925 | 47.1 | 45.7 | 19.5 | 57.6 | N/R | 94.3 | 82.9 | 97.6 | 7.1 |
| Kim 201426 | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R |
N/R = data not reported in primary paper.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
